1. Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR et al (1993). Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 15: 91–96.
2. Anderson GM, Braun G, Braun U, Nichols DE, Shulgin AT (1978). Absolute configuration and psychomimetic activity. NIDA Res Monogr 22: 8–15.
3. Axt K, Mamounas L, Molliver M (1994). Structural features of amphetamine neurotoxicity. In: Cho AK, Segal DS (eds). Amphetamine and its Analogs. Academic Press: San Diego, CA. pp 315–370.
4. Battaglia G, Yeh SY, O’Hearn E, Molliver ME, Kuhar MJ, Desouza EB (1987). 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of 3H paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242: 911–916.
5. Bendotti C, Baldessari S, Pende M, Tarizzo G, Miari A, Presti ML et al (1994). Does GFAP mRNA and mitochondrial benzodiazepine receptor binding detect serotonergic neuronal degeneration in rat? Brain Res Bull 34: 389–394.